Key Takeaways
- HIMS shares climbed 7% in Thursday’s premarket session, building on Wednesday’s 10% advance and marking a fourth consecutive day of positive momentum
- The telehealth company’s stock has jumped 64% week-to-date — marking its strongest weekly showing in company history
- The dramatic climb followed announcement of a distribution agreement with Novo Nordisk, enabling HIMS to offer FDA-cleared Ozempic and Wegovy through its platform
- Barclays boosted its price objective from $25 to $29 with an “overweight” stance; Bank of America shifted from “underperform” to “neutral” with a $23 target
- Fourth-quarter EPS of $0.08 crushed the $0.02 analyst forecast, while revenue of $617.8M came in marginally below the $619.5M projection
Hims & Hers Health (HIMS) is experiencing a breakthrough week for the record books. The telehealth stock gained approximately 7% in Thursday’s premarket activity after advancing 10% during Wednesday’s regular session. This extends the winning streak to four consecutive trading days.
Hims & Hers Health, Inc., HIMS
As of Wednesday’s market close, HIMS has rocketed 64% higher over the five-day period. This represents the company’s most impressive weekly gain since going public.
The momentum ignited Monday following reports that Novo Nordisk agreed to supply its popular weight-loss medications through the Hims & Hers digital platform. The arrangement resolves a legal uncertainty that had weighed on investor sentiment.
The collaboration enables Hims & Hers to distribute FDA-sanctioned Ozempic and Wegovy to consumers via its telemedicine service. Industry analysts view this as a meaningful catalyst for both top-line growth and profit margins.
HIMS shares changed hands at $26.17 during Wednesday’s midday trading, reflecting a $2.70 increase, while volume reached 51.6 million shares — substantially higher than the typical 33.3 million daily average.
Wall Street Analysts Raise Price Targets
The Novo Nordisk collaboration prompted several analyst firms to revise their outlooks. Barclays elevated its price objective from $25 to $29 while maintaining an “overweight” recommendation. This suggests approximately 10.8% appreciation potential from present levels.
Bank of America revised its rating from “underperform” to “neutral” and increased its target from $12.50 to $23. Deutsche Bank lifted its objective from $25 to $28 while keeping a “hold” designation.
According to MarketBeat consensus data, the average price target stands at $30.75 with an overall “Hold” rating. The breakdown includes three Buy ratings, thirteen Hold recommendations, and one Sell rating.
Options traders showed heightened interest, with roughly 322,000 call contracts changing hands — indicating significant bullish sentiment that could accelerate price movements.
Fourth Quarter Results and Capital Allocation
HIMS disclosed Q4 financial results on February 23. Earnings per share reached $0.08, substantially exceeding the $0.02 Wall Street consensus. Revenue totaled $617.8 million, narrowly missing the $619.5 million estimate.
Despite the minor revenue shortfall, sales increased 28.4% compared to the prior-year period. The company achieved a return on equity of 22.48% alongside a net profit margin of 5.47%.
The board authorized a $250 million share repurchase program, representing approximately 3% of shares outstanding. Such buyback initiatives often indicate management confidence that shares are trading below intrinsic value.
For the current fiscal year, Wall Street analysts project full-year EPS of $0.29.
The stock’s 52-week trading range spans from $13.74 to $70.43. At Wednesday’s closing price, shares trade comfortably above the 50-day moving average of $24.31 but remain beneath the 200-day moving average of $37.75.
Notwithstanding this week’s powerful advance, short interest warrants monitoring. Analysts have noted that squeeze dynamics could introduce volatility — as gains fueled by short covering may reverse abruptly when speculative momentum dissipates.
Institutional investors control 63.52% of outstanding HIMS shares. Company insiders own 17.71%, though they divested 80,463 shares during the most recent quarter.
